Anzeige
Mehr »
Login
Donnerstag, 16.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
148 Leser
Artikel bewerten:
(0)

Myant Corp.: Myant Accelerates Precision Healthcare with Acquisition of Bitnobi Inc.

Finanznachrichten News

TORONTO, Jan. 16, 2025 /PRNewswire/ -- Myant, a global leader in advanced materials and connected health solutions, proudly announces the acquisition of Toronto-based technology innovator, Bitnobi Inc. Spun out of York University with the support of Toronto Innovation Acceleration Partners (TIAP), Bitnobi specializes in privacy-protected data-sharing software. Their groundbreaking platform facilitates secure collaboration between data owners and consumers without compromising raw data-a critical capability in today's healthcare landscape.

Myant Logo

This marks Myant's fourth strategic acquisition in just six months, each one bolstering its platform with new technologies, capabilities, and markets. Together, these moves are driving Myant closer to its bold mission: empowering people to live younger for longer through proactive, personalized, and precision healthcare solutions.

The acquisition of Bitnobi fills a critical gap in the third pillar of Myant's strategy: safe and secure data sharing. By integrating Bitnobi's patented platform, Myant advances its ability to create a "digital human replica," an innovative approach to personalizing healthcare through insights generated from its smart material solution

"Myant is building the equivalent of a fiber-optic connection to the human body which enables a true digital replica," said Tony Chahine, Myant's founder and CEO. "We aim to connect the human operating system-its rhythms, signals, and unique needs-use advanced materials, AI, and sensing to deliver proactive and preventative care. This acquisition strengthens our ability to provide precise and personalized support that goes beyond reactive healthcare."

Expanding the Boundaries of Data Sharing and Collaboration

Through this acquisition, Myant enhances its capacity to share and utilize healthcare data responsibly and effectively. The company will not only be able to share its proprietary data with researchers and clinicians but also securely access third-party data while respecting governance protocols.

The partnership will also drive new data-sharing collaborations across Canada and internationally, unlocking valuable health insights and fostering innovation. "Bitnobi enables us to create seamless, secure pathways for data sharing that respect privacy while opening new doors for healthcare innovation," Chahine added.

A Proven Platform for the Future of Precision Healthcare

Since its founding in 2016, Bitnobi has supported significant initiatives, including Canada's Digital Health and Discovery Platform (DHDP). By enabling secure management of digital health data, Bitnobi is accelerating precision medicine for cancer and other diseases. Now, as part of Myant, Bitnobi's expertise in big data, cloud computing, and cybersecurity will amplify innovation across Myant's textile computing, smart materials, and data integration efforts.

Hassan Jaferi, CEO of Bitnobi, emphasized the alignment of the two companies' missions: "Myant has created a global innovation hub in Toronto, where over 200 scientists, engineers, and researchers are driving breakthroughs in connected health. Joining forces will amplify our collective impact, ensuring that innovation in Canada's technology and healthcare sectors continues to thrive."

Shaping the Future of Healthcare

This acquisition underscores Myant's commitment to proactive, precision healthcare. By integrating advanced materials, intelligent interfaces, and secure data sharing, Myant is not only redefining health and aging but also positioning itself as a global leader in innovation.

Together, Myant and Bitnobi are shaping a future where healthcare is proactive, personalized, precise and preventative-empowering individuals to live healthier, longer, and more independent lives.

About Myant
Myant is leading a new era of evolution where AI guardians enhance human capabilities through textile interfaces that function like a connected second skin. This second skin - made possible by groundbreaking advanced materials - blends naturally into our everyday lives, setting a new standard for seamless interaction with the digital world.

About Bitnobi
Bitnobi Inc. is a technology startup focused on the commercialization of a privacy protected, data sharing platform. Bitnobi was spun out of research from Dr. Marin Litoiu's laboratory at York University with full support from the Toronto Innovation Acceleration Partners and Innovation York. Headquartered in Toronto, Canada, Bitnobi has also received assistance from the Natural Sciences and Engineering Research Council of Canada, Ontario Centres of Innovation, Seneca College, National Research Council of Canada's Industrial Research Assistance Program, Rogers Cybersecure Catalyst, MaRS Discovery District and Canada's Digital Health and Discovery Platform.

For more information, please contact:
Charles Andreo
info@myant.ca
www.myant.ca

Logo - https://mma.prnewswire.com/media/2569573/5120589/Myant_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/myant-accelerates-precision-healthcare-with-acquisition-of-bitnobi-inc-302353407.html

© 2025 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.